Goldman Sachs’s Lunai Bioworks Inc. Common Stock RENB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $172K | Buy |
594,988
+412,934
| +227% | +$119K | ﹤0.01% | 4767 |
|
|
2025
Q1 | $98.9K | Sell |
182,054
-182,425
| -50% | -$99.1K | ﹤0.01% | 4822 |
|
|
2024
Q4 | $305K | Buy |
364,479
+271,594
| +292% | +$227K | ﹤0.01% | 4522 |
|
|
2024
Q3 | $44.9K | Buy |
92,885
+33,806
| +57% | +$16.3K | ﹤0.01% | 4671 |
|
|
2024
Q2 | $103K | Sell |
59,079
-247,065
| -81% | -$432K | ﹤0.01% | 4495 |
|
|
2024
Q1 | $811K | Buy |
306,144
+293,273
| +2,279% | +$777K | ﹤0.01% | 3736 |
|
|
2023
Q4 | $40.8K | Buy |
+12,871
| New | +$40.8K | ﹤0.01% | 4565 |
|
|
2023
Q3 | – | Sell |
-118,105
| Closed | -$66.9K | – | 4906 |
|
|
2023
Q2 | $66.9K | Buy |
118,105
+104,273
| +754% | +$59.1K | ﹤0.01% | 4630 |
|
|
2023
Q1 | $12.7K | Buy |
+13,832
| New | +$12.7K | ﹤0.01% | 4929 |
|
|
2022
Q2 | – | Sell |
-82,883
| Closed | -$684K | – | 5823 |
|
|
2022
Q1 | $684K | Buy |
82,883
+17,260
| +26% | +$142K | ﹤0.01% | 4385 |
|
|
2021
Q4 | $478K | Buy |
65,623
+40,366
| +160% | +$294K | ﹤0.01% | 4554 |
|
|
2021
Q3 | $170K | Sell |
25,257
-17,211
| -41% | -$116K | ﹤0.01% | 4919 |
|
|
2021
Q2 | $211K | Sell |
42,468
-12,954
| -23% | -$64.4K | ﹤0.01% | 4890 |
|
|
2021
Q1 | $196K | Buy |
+55,422
| New | +$196K | ﹤0.01% | 4850 |
|
|
2019
Q3 | – | Sell |
-16,249
| Closed | -$73K | – | 4319 |
|
|
2019
Q2 | $73K | Sell |
16,249
-96,790
| -86% | -$435K | ﹤0.01% | 4049 |
|
|
2019
Q1 | $784K | Buy |
+113,039
| New | +$784K | ﹤0.01% | 3375 |
|